Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey.
Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey.
复制标题
DOI：
10.1007/s00296-021-04917-0
复制
发表时间：
2021-08
影响因子：
4
通讯作者：
Shenoy P
中科院分区：
文献类型：
--
作者：
Cherian S;Paul A;Ahmed S;Alias B;Manoj M;Santhosh AK;Varghese DR;Krishnan N;Shenoy P
患有风湿性和肌肉骨骼（RMD）疾病的患者感染COVID-19的风险可能更高。关于该组中腺病毒载体携带的ChAdOx 1 nCoV-19和热灭活的BBV 152疫苗的安全性数据有限。对724名接受过至少一剂ChAdOx 1或BBV 152的RMD患者进行了审计，以找出疫苗接种后的不良反应（AE）或疾病发作。比较自身免疫性风湿病（AIRD）与非AIRD RMD患者的AE发生率。队列的平均年龄为59.9（± 10.43）岁，女性（n = 581; 80.24%）占多数。523例（70.8%）有AIRD。接种ChAdOx 1和BBV 152疫苗的分别为624例（86.18%）和77例（10.63%）。23例（3.17%）不知道接种了哪种疫苗。238例（32.87%）患者至少有一种合并症。436例（60.22%）受试者[306例（59.64%）AIRD患者和130例（61.61%）其他RMD患者]至少有一种不良反应（AE）。4例患者报告关节炎发作，5天内消退。无患者发生任何重度AE或需要住院治疗。所有AE均为自限性。ChAdOx 1和BBV 152疫苗在RMD中似乎都是安全的。AEs在AIRD患者和非AIRD患者之间没有差异。这些信息可以帮助消除所有利益相关者对疫苗的犹豫。在线版本包含补充材料，可通过10.1007/s 00296 -021-04917-0获得。
Patients with rheumatic and musculoskeletal (RMD) diseases may be at higher risks for COVID-19 infection. Data on the safety of the adenoviral vector-borne ChAdOx1 nCoV-19 and the heat-inactivated BBV152 Vaccines in this group are limited. 724 patients with RMD who had received at least one dose of either the ChAdOx1 or the BBV152 were audited to find out post-vaccination adverse effect (AE) or disease flares. The AE rates in patients with autoimmune rheumatic disease (AIRD) were compared with those with non-AIRD RMDs. The mean age of the cohort was 59.9 (± 10.43) years with a female (n = 581; 80.24%) majority. 523 (70.8%) had AIRD. The ChAdOx1 and the BBV152 vaccines were received by 624 (86.18%) and 77 (10.63%), respectively. 23 (3.17%) were unaware of which vaccine they had received. 238 (32.87%) of patients had at least one comorbidity. 436 (60.22%) participants [306 (59.64%) of those with AIRD and 130 (61.61%) with other RMDs] had at least one adverse effect (AE). Four patients reported flare of arthritis that resolved within 5 days. No patient had any severe AE or required hospitalization. All AEs were self-limiting. Both the ChAdOx1 and the BBV152 vaccines appear safe in RMDs. AEs do not differ between patients with AIRD or non-AIRD. This information can help negate vaccine hesitancy amongst all stakeholders. The online version contains supplementary material available at 10.1007/s00296-021-04917-0.
登录
查看更多内容
DOI：
10.1016/s0140-6736(20)32661-1
发表时间：
2021-01-09
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Clemens SAC;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Collins AM;Colin-Jones R;Cutland CL;Darton TC;Dheda K;Duncan CJA;Emary KRW;Ewer KJ;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Goodman AL;Green CM;Green CA;Heath PT;Hill C;Hill H;Hirsch I;Hodgson SHC;Izu A;Jackson S;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Lawrie AM;Lelliott A;Libri V;Lillie PJ;Mallory R;Mendes AVA;Milan EP;Minassian AM;McGregor A;Morrison H;Mujadidi YF;Nana A;O'Reilly PJ;Padayachee SD;Pittella A;Plested E;Pollock KM;Ramasamy MN;Rhead S;Schwarzbold AV;Singh N;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Tarrant R;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;Watson MEE;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
影响因子：
4
作者：
Wang Q;Liu J;Shao R;Han X;Su C;Lu W
通讯作者：
Lu W
影响因子：
6.2
作者：
Schulze-Koops H;Specker C;Skapenko A
通讯作者：
Skapenko A
影响因子：
4
作者：
Velikova T;Georgiev T
通讯作者：
Georgiev T
影响因子：
13.3
作者：
Curtis, Jeffrey R.;Johnson, Sindhu R.;Mikuls, Ted R.
通讯作者：
Mikuls, Ted R.